Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia
Open Access
- 16 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5192-5200
Abstract
Selection of a suitable donor for allogeneic hematopoietic stem cell transplantation (allo-HCT) has mainly relied on HLA matching and, to date, a matched sibling donor (MSD) remains the first choice. However, patients with acute myeloid leukemia (AML) are older and therefore tend to have older siblings. Haploidentical donors (HIDs) are easily available, and offspring are younger than siblings. As donor age has been associated with worse outcomes, a younger HID might be a better choice than an older MSD for older patients with AML who receive transplantation in first complete remission (CR1). From the European Society for Blood and Marrow Transplantation registry database, we selected patients with AML aged ≥60 years who received transplantation in CR1, either from MSD aged ≥50 years or HID ≤40 years. HIDs received posttransplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis, and MSDs received in vivo T-cell depletion. A total of 1247 patients were identified, including 721 MSDs and 526 HIDs. In univariate analysis, HID was associated with lower relapse incidence (P = .01), higher nonrelapse mortality (NRM; P = .01). The 2-year probability of overall survival (OS), leukemia-free survival (LFS), and GVHD-free and relapse-free survival (GRFS) were 62.5%, 56%, and 47%, respectively for the all population. In multivariate analysis, we confirmed that HID was associated with less relapse but more NRM, which translated into similar OS, LFS, and GRFS. Based on this retrospective study, young HIDs led to less relapse but higher NRM than older MSDs after allo-HCT in an older population with AML in CR1.Keywords
This publication has 56 references indexed in Scilit:
- Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2015
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter studyTransfusion, 2014
- Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Blood, 2013
- Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow TransplantationSeminars in Oncology, 2012
- Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblingsLeukemia, 2012
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- The frequency of regulatory CD3+CD8+CD28−CD25+ T lymphocytes in human peripheral blood increases with ageJournal of Leukocyte Biology, 2008
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007
- The Aging Immune System: Primer and ProspectusScience, 1996